NCT02372227 2017-01-30A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant MesotheliomaVerastem, Inc.Phase 1 Terminated21 enrolled
NCT01991938 2017-01-27Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or LymphomaVerastem, Inc.Phase 1 Terminated75 enrolled